Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Allk save search
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-03-14 (Crawled : 20:00) - globenewswire.com
ALLK | $1.055 -0.47% -0.47% 270K
|
Health Technology
|
| O: -1.15%
H: 2.33%
C: 1.55%
business year update financial results
Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024
Published: 2024-02-26 (Crawled : 12:00) - globenewswire.com
ALLK | $1.055 -0.47% -0.47% 270K
|
Health Technology
|
| O: 2.21%
H: 10.07%
C: 5.04%
ak006 cell preclinical
Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition
Published: 2024-02-12 (Crawled : 12:00) - globenewswire.com
ALLK | $1.055 -0.47% -0.47% 270K
|
Health Technology
|
| O: 1.49%
H: 10.29%
C: 2.21%
ak006 publication cell
Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints
Published: 2024-01-16 (Crawled : 12:00) - globenewswire.com
ALLK | $1.055 -0.47% -0.47% 270K
|
Health Technology
|
| O: -59.2%
H: 10.66%
C: -2.46%
urticaria dermatitis trials
Allakos Announces a Restructuring to Focus on Development of AK006
Published: 2024-01-16 (Crawled : 12:00) - globenewswire.com
ALLK | $1.055 -0.47% -0.47% 270K
|
Health Technology
|
| O: -59.2%
H: 10.66%
C: -2.46%
ak006
Allakos Appoints Neil Graham to its Board of Directors
Published: 2023-08-30 (Crawled : 20:00) - globenewswire.com
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 0.11%
H: 0.0%
C: -1.12%
ASLN | News | $0.4645 2.09% 2.05% 1.5M
|
Health Technology
|
| O: 1.9%
H: 0.93%
C: -0.7%
ALLK | $1.055 -0.47% -0.47% 270K
|
Health Technology
|
| O: 1.02%
H: 5.17%
C: -2.7%
Allakos Appoints Rand Sutherland and Dolca Thomas to its Board of Directors
Published: 2023-08-02 (Crawled : 20:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -1.6%
H: 0.11%
C: 0.11%
TBIO | $0.32 1.52% 1.5% 140K
|
Health Technology
|
| O: -0.69%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -3.79%
H: 0.0%
C: 0.0%
KRYS | News | $162.175 3.13% 3.04% 220K
|
Health Technology
|
| O: -2.31%
H: 0.73%
C: -1.14%
EQ | $1.77 7.27% 6.78% 88K
|
Health Technology
|
| O: 9.59%
H: 7.68%
C: -6.75%
KDNY | $40.39 0.22% -0.17% 0
|
Health Technology
|
| O: 0.02%
H: 0.26%
C: 0.22%
ALLK | $1.055 -0.47% -0.47% 270K
|
Health Technology
|
| O: -0.91%
H: 1.84%
C: -1.1%
Allakos Presents Preclinical Data at EAACI Hybrid Congress 2023 Highlighting Lirentelimab and AK006 Mechanisms of Mast Cell Inhibition
Published: 2023-06-12 (Crawled : 11:00) - globenewswire.com
ALLK | $1.055 -0.47% -0.47% 270K
|
Health Technology
|
| O: 0.0%
H: 5.21%
C: 2.71%
ak006 cell preclinical
Allakos Announces Upcoming Presentation on Lirentelimab and AK006 Mast Cell Inhibition at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2023
Published: 2023-06-05 (Crawled : 11:00) - globenewswire.com
ALLK | $1.055 -0.47% -0.47% 270K
|
Health Technology
|
| O: 0.0%
H: 0.95%
C: -2.29%
ak006 presentation cell immunology
Allakos Provides Business Update and Reports First Quarter 2023 Financial Results
Published: 2023-05-09 (Crawled : 20:00) - globenewswire.com
ALLK | $1.055 -0.47% -0.47% 270K
|
Health Technology
|
| O: 0.46%
H: 5.54%
C: -0.92%
business update financial results
Urticaria Drugs Market size to grow by USD 1.31 billion from 2021 to 2026, Driven by the growth in incidence of urticaria - Technavio
Published: 2023-04-04 (Crawled : 22:00) - prnewswire.com
GLAXF | News | $20.305 -14.18% 630
|
Health Technology
|
| O: 1.79%
H: 3.07%
C: 3.07%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.69%
H: 0.0%
C: 0.0%
NVSEF | News | $95.11 6.88% 490
|
Health Technology
|
| O: 1.57%
H: 1.01%
C: 0.96%
VTRS | News A | $11.36 0.98% 0.97% 4.7M
|
Health Technology
|
| O: -0.1%
H: 3.15%
C: 2.94%
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
|
| O: 1.29%
H: 0.83%
C: 0.4%
GSK | News | $41.24 1.6% 0.0% 2.3M
|
Health Technology
|
| O: 1.2%
H: 1.32%
C: 1.24%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 1.58%
H: 0.0%
C: 0.0%
ALLK | $1.055 -0.47% -0.47% 270K
|
Health Technology
|
| O: -0.96%
H: 1.21%
C: -0.24%
urticaria growth market
Allakos Announces Publication of AK006 Mechanism of Action Manuscript in Communications Biology
Published: 2022-11-29 (Crawled : 12:20) - globenewswire.com
ALLK | $1.055 -0.47% -0.47% 270K
|
Health Technology
|
| O: 0.54%
H: 9.19%
C: 7.3%
ak006 communications publication
Allakos Presents Preclinical Data on AK007, a Siglec-10 Antagonist Antibody, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting
Published: 2022-11-10 (Crawled : 16:00) - biospace.com/
ALLK | $1.055 -0.47% -0.47% 270K
|
Health Technology
|
| O: 3.6%
H: 2.17%
C: 2.17%
ak007 preclinical immunotherapy meeting
USD 1.31 Bn growth for Urticaria Drugs Market through 2026: Analysing growth for Pharmaceuticals - Technavio
Published: 2022-09-29 (Crawled : 09:00) - prnewswire.com
GLAXF | News | $20.305 -14.18% 630
|
Health Technology
|
| O: -3.32%
H: 4.73%
C: 4.73%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.22%
H: 0.33%
C: 0.33%
NVSEF | News | $95.11 6.88% 490
|
Health Technology
|
| O: 1.87%
H: 0.0%
C: 0.0%
VTRS | News A | $11.36 0.98% 0.97% 4.7M
|
Health Technology
|
| O: -1.26%
H: 0.7%
C: -0.23%
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
|
| O: 0.17%
H: 1.1%
C: 0.16%
GSK | News | $41.24 1.6% 0.0% 2.3M
|
Health Technology
|
| O: -0.14%
H: 0.53%
C: -0.2%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.13%
H: 0.0%
C: 0.0%
ALLK | $1.055 -0.47% -0.47% 270K
|
Health Technology
|
| O: -2.77%
H: 2.14%
C: -0.18%
pharmaceuticals urticaria growth market
Allakos Announces Pricing of $150 Million Underwritten Offering of Common Stock
Published: 2022-09-19 (Crawled : 13:00) - biospace.com/
ALLK | $1.055 -0.47% -0.47% 270K
|
Health Technology
|
| O: 16.59%
H: 14.79%
C: 9.36%
offering
Allakos Announces Topline Phase 3 Data from the EoDyssey Study in Patients with Eosinophilic Duodenitis
Published: 2022-09-09 (Crawled : 22:00) - biospace.com/
ALLK | $1.055 -0.47% -0.47% 270K
|
Health Technology
|
| O: -8.41%
H: 18.12%
C: 15.41%
topline study
Allakos Announces the Appointment of Dr. Amy Ladd to its Board of Directors
Published: 2022-07-25 (Crawled : 00:00) - biospace.com/
ISRG | $377.11 2.22% 2.17% 1.8M
|
Health Technology
|
| O: 0.64%
H: 4.03%
C: 2.8%
ALLK | $1.055 -0.47% -0.47% 270K
|
Health Technology
|
| O: -0.26%
H: 0.71%
C: -4.42%
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
Published: 2022-03-01 (Crawled : 23:00) - globenewswire.com
ALLK | $1.055 -0.47% -0.47% 270K
|
Health Technology
|
| O: -2.02%
H: 7.5%
C: 4.5%
financial results report results
Allakos Announces Topline Phase 3 Data from the ENIGMA 2 Study and Phase 2/3 Data from the KRYPTOS Study in Patients with Eosinophilic Gastrointestinal Diseases
Published: 2021-12-22 (Crawled : 01:00) - globenewswire.com
ALLK | $1.055 -0.47% -0.47% 270K
|
Health Technology
|
| O: -87.46%
H: 2.55%
C: -19.19%
phase 2 phase 2/3 gastrointestinal disease test topline phase 3
Allakos Announces Expansion of Lirentelimab Development into Atopic Dermatitis, Chronic Spontaneous Urticaria and Asthma
Published: 2021-11-30 (Crawled : 15:00) - biospace.com/
ALLK | $1.055 -0.47% -0.47% 270K
|
Health Technology
|
| O: -0.92%
H: 0.0%
C: 0.0%
atopic dermatitis expansion dermatitis urticaria
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.